Clearmind Medicine Announces 1-for-40 Reverse Share Split

Core Viewpoint - Clearmind Medicine Inc. will conduct a reverse share split at a ratio of 1-for-40 to regain compliance with the Nasdaq Minimum Bid Price Rule, effective December 15, 2025 [1][2]. Group 1: Reverse Share Split Details - The reverse share split was approved by the Company's board of directors on November 12, 2025 [2]. - Following the reverse split, the number of issued and outstanding Common Shares will decrease from 59,991,852 to 1,499,796 [3]. - No fractional Common Shares will be issued; all fractional shares will be rounded up to the nearest whole share [4]. Group 2: Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health issues, including alcohol use disorder [5]. - The Company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5].